Departament of Endocrine and General Surgery, Medical University of Lodz, Copernicus Memorial Hospital, Lodz, Poland.
Arch Med Res. 2010 Apr;41(3):190-4. doi: 10.1016/j.arcmed.2010.04.004.
Vitamin D(3), in addition to its role in calcium homeostasis, has been recognized as playing a role in human cancer development. However, little is known about the association between vitamin D status and the development of thyroid cancer. This study aimed to investigate vitamin D metabolism by measuring 25(OH) D(3), 1-25 (OH)(2) D(3), PTH and calcium concentrations in the peripheral blood of patients with different forms of thyroid tumors.
The 25-hydroxyvitamin D(3) ,1-25- dihydoxyvitamin D(3), PTH and calcium serum levels of 50 consecutive patients with epithelial thyroid cancer 27 cases of papillary cancers (PTC), 16 follicular cancers (FTC), and seven cases of anaplastic cancers (ATC) and 34 multinodular nontoxic goiter (MNG) were measured by specific immunoassay. The control group consisted of 26 healthy volunteers.
Our results revealed significantly lower 1-25 (OH)(2) D(3) concentration in the PTC group (22.67 pg/mL +/- 8.12; p <0.05), FTC group (16.09 pg/mL +/- 6.15; p <0.02) and ATC group (9.48 pg/mL +/- 5.18; p <0.02). Levels of 1-25 (OH)(2) D(3) varied by cancer stage and were also significantly different. A significant decrease in circulating 1-25 (OH)(2) D(3) concentration was found in patients with stage I (24.12 pg/mL +/- 6.77; p <0.05), stage II (16.93 pg/mL +/- 4.55; p <0.05), stage III (12.44 +/- 8.98; p <0.02) and in stage IVa (6.18 +/- 2.22; p <0.01). There were no significant differences when comparing serum levels of 25(OH) D(3), PTH or calcium concentrations among individuals with multinodular goiter, thyroid cancer and age- and sex-matched control volunteers.
Our study revealed that impaired vitamin D(3) metabolism may play an important role in thyroid follicular cell oncogenesis.
维生素 D（3）除了在钙稳态中的作用外，还被认为在人类癌症发展中发挥作用。然而，关于维生素 D 状态与甲状腺癌发展之间的关系知之甚少。本研究旨在通过测量外周血中的 25（OH）D（3）、1-25（OH）（2）D（3）、PTH 和钙浓度，来研究不同形式甲状腺肿瘤患者的维生素 D 代谢。
连续测量了 50 例上皮性甲状腺癌患者（27 例乳头状癌 [PTC]、16 例滤泡癌 [FTC]和 7 例间变性癌 [ATC]）、34 例多结节性非毒性甲状腺肿（MNG）的 25-羟维生素 D（3）、1-25-二羟维生素 D（3）、PTH 和钙血清水平。对照组由 26 名健康志愿者组成。
我们的结果显示，PTC 组（22.67 pg/mL +/- 8.12；p <0.05）、FTC 组（16.09 pg/mL +/- 6.15；p <0.02）和 ATC 组（9.48 pg/mL +/- 5.18；p <0.02）1-25（OH）（2）D（3）浓度明显较低。1-25（OH）（2）D（3）水平随癌症分期而变化，差异也有统计学意义。发现 I 期（24.12 pg/mL +/- 6.77；p <0.05）、II 期（16.93 pg/mL +/- 4.55；p <0.05）、III 期（12.44 +/- 8.98；p <0.02）和 IVa 期（6.18 +/- 2.22；p <0.01）患者的循环 1-25（OH）（2）D（3）浓度显著降低。多结节性甲状腺肿、甲状腺癌患者与年龄和性别匹配的对照组志愿者的血清 25（OH）D（3）、PTH 或钙浓度比较无显著差异。
我们的研究表明，维生素 D（3）代谢受损可能在甲状腺滤泡细胞癌变中发挥重要作用。
